Filing Flows

Filing Flows › Kymera Therapeutics (KYMR) › Who owns the stock

Who owns Kymera Therapeutics (KYMR) stock

276 funds reported Kymera Therapeutics (KYMR) shares in their latest 13F filings, worth $11.4B in all. The largest holder is FMR LLC ($1.4B). Last quarter 127 funds added to their stakes and 99 cut them.

Largest holders of KYMR (13F)Largest holders of KYMR (13F)FMR LLC$1.4BBaker Bros. Advisors LP$993MAvoro Capital Advisors LLC$857MPrice T Rowe Associates$816MT. Rowe Price Investment Manageme…$718MBlackRock$635MVanguard Group$488MBVF$444MWellington Management Group LLP$421MVanguard Portfolio Management LLC$343M

Largest holders (13F)

FundSharesValueChangeQuarter
FMR LLC12,349,256$1.4Bincrease2026-06-30
Baker Bros. Advisors LP8,657,242$993Munchanged2026-06-30
Avoro Capital Advisors LLC7,474,747$857Munchanged2026-06-30
Price T Rowe Associates7,112,980$816Mincrease2026-06-30
T. Rowe Price Investment Management6,257,261$718Mincrease2026-06-30
BlackRock5,538,210$635Mincrease2026-06-30
Vanguard Group6,267,644$488Mincrease2025-12-31
BVF3,872,052$444Mdecrease2026-06-30
Wellington Management Group LLP3,675,028$421Mdecrease2026-06-30
Vanguard Portfolio Management LLC2,992,193$343Mincrease2026-06-30
Siren, L.L.C.2,935,830$337Mdecrease2026-06-30
Vanguard Capital Management LLC2,932,378$336Mincrease2026-06-30
Atlas Venture Life Science Advisors, LLC2,847,541$327Mdecrease2026-06-30
State Street2,737,226$314Mincrease2026-06-30
Geode Capital Management, LLC1,816,331$208Mincrease2026-06-30

Kymera Therapeutics' latest quarter

Kymera Therapeutics, Q2 2026: revenue $65.0M (+466% year over year), operating margin -116.3%, net loss $61.2M, operating cash flow −$54.1M. The chart follows the revenue to costs, profit and cash.

Questions

Who owns the most KYMR stock?

By the latest 13F filings: FMR LLC ($1.4B); Baker Bros. Advisors LP ($993M); Avoro Capital Advisors LLC ($857M); Price T Rowe Associates ($816M); T. Rowe Price Investment Management ($718M).

What is the short interest in KYMR?

9,171,421 shares were sold short at the 2026-10-15 settlement, -7.45% of the float.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.